DALLAS (AP) — DALLAS (AP) — Kronos Worldwide Inc. (KRO) on Thursday reported a loss of $37 million in its third quarter. On a per-share basis, the Dallas-based company said it had a loss of 32 cents.

Lexus will unveil the new LS Concept at the 2025 Japan Mobility Show, a radical vision that redefines contemporary luxury. More than a vehicle, the LS Concept represents a statement of principles: the ...

This Vault is located in the North of War's Den, specifically North-East of Protector Drakon Ismenios. It's guarded by several challenging monsters. The chest for this Vault requires the Heavy Lifting ...

Lexus is solely offering the 2026 LS sedan in a new Heritage Edition, a 250-unit which celebrates its 36 years on the market. However, not all things last forever. In the past few years, the sales ...

Back in 1955, General Motors gave birth to one of America's most iconic engines, the Chevy small-block V8. Among these, the LS series, also known as the third and fourth generations of small block V8, ...

Investing in stocks inevitably means buying into some companies that perform poorly. But long term Kronos Worldwide, Inc. (NYSE:KRO) shareholders have had a particularly rough ride in the last three ...

(RTTNews) - Kronos Bio (KRON) has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common ...

Kronos Bio is vacating its corporate headquarters amid a wider cost-cutting exercise for the struggling biotech. The company, which has been focused on developing small-molecule drugs for cancers and ...

Chevrolet introduced the legendary LS V8 engine to the world way back in 1997 as the engine powering the new C5 Corvette. That first engine, the LS1, was a 5.7 liter, aluminum block, pushrod V8 that, ...

Kronos Bio, a San Mateo biotech company, is losing millions of dollars a month and recently had to discontinue its sole clinical-stage compound because of adverse side effects. Now, the company is ...

On the heels Kronos Bio’s decision to can its last remaining clinical asset earlier this month, the company said it would roll out “significant expense reduction strategies” to buy itself more time.